Importantly, we show that targeting Rac1 can effectively block the lung metastatic and tumor initiating activities of both SP and non-SP NSCLA cells, and such benefits may apply to the CD133+/CD133− tumor initiating populations. This evidence concerns the gene PROM1 and neoplasm.